ClinicalTrials.gg

Program

GT719

A development code. Also written as “GT719 Injection”.

Its studies are mostly in Hematologic Neoplasms · Autoimmune Diseases, led by Grit Biotechnology.

Furthest: phase 2, since Apr 22, 20255 company-led studies, 5 open or runningNext primary completion: Dec 1, 2027 (early phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grit Biotechnology55 open or runningphase 2since Apr 22, 2025Apr 22, 2025Dec 1, 2027early phase 1 · NCT07131254

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2025First study: phase 2 study in Hematologic NeoplasmsFirst studyNCT06948981 · 46 planned · China
  2. May 29, 2025Phase 1 study in Neurological Autoimmune DiseasesNCT07021209 · 30 planned · China
  3. Jun 26, 2025Early phase 1 study in Hematologic NeoplasmsNCT07131254 · 34 planned · China
  4. Jul 29, 2025Early phase 1 study in Autoimmune DiseasesNCT07122076 · 10 planned · China
  5. Aug 14, 2025Early phase 1 study in Auto Immune DiseaseNCT07132112 · 30 planned · China

Ahead

  1. Dec 1, 2027Primary completion: early phase 1 study in Hematologic NeoplasmsNCT07131254
  2. Jan 13, 2028Primary completion: phase 1 study in Neurological Autoimmune DiseasesNCT07021209
  3. Apr 17, 2028Primary completion: phase 2 study in Hematologic NeoplasmsNCT06948981
  4. Aug 2028Primary completion: early phase 1 study in Auto Immune DiseaseNCT07132112

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07132112Auto Immune Disease · ChinaEarly 1RecruitingAug 202830
NCT07122076Autoimmune Diseases · ChinaEarly 1RecruitingAug 21, 202810
NCT07131254Hematologic Neoplasms · ChinaEarly 1RecruitingDec 1, 202734
NCT07021209Neurological Autoimmune Diseases · China1RecruitingJan 13, 202830
NCT06948981Hematologic Neoplasms · China2RecruitingApr 17, 202846

How it is read

Names in the registry

  • “GT719 Injection”, 5 entries

Codes read as this program: GT719.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
GT719 (Grit Biotechnology): development program | ClinicalTrials.gg